Beta Bionics, Inc. (NASDAQ: BBNX) has priced a $150 million public offering this week just as its product story is acquiring more commercial torque: FDA clearance for the Mint™ patch pump, a planned U.S. launch in the first quarter of 2027, and a…
Apple Inc. (NASDAQ: AAPL) is betting that the next smartphone upgrade cycle will fold neatly into consumers’ pockets, while Amwell (NYSE: AMWL) is positioning its virtual-care platform for a potentially consequential role inside the U.S. Department of Veterans Affairs. Together, the developments…
Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…
Revolution Medicines, Inc. (NASDAQ: RVMD) seems to have crossed the line that separates a compelling biotech hypothesis from a commercial oncology story: the U.S. Food and Drug Administration approved its first medicine, RASONQUE (daraxonrasib), for certain adults with metastatic pancreatic adenocarcinoma. The approval…
Amwell, Inc. (NYSE: AMWL, $12.40, up +152.55% YTD) is building a more investable telehealth narrative: less pandemic-era novelty, more enterprise healthcare infrastructure. Its second-quarter results suggest the company is translating a broad digital-care footprint into a steadier mix of recurring subscription revenue,…
This bullish market story examines how rising bond yields are reshaping—not ending—the investment opportunity set. It highlights **NVIDIA (NASDAQ: NVDA)** and its enormous AI data-center ambitions, **Alphabet (NASDAQ: GOOGL, GOOG)** and the growing strategic value of proprietary business data, and the emerging…
For patients with eosinophilic esophagitis, eating can become an exercise in calculated risk rather than a simple pleasure. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), that burden represents both an urgent medical problem and a potentially compelling opportunity to prove that…
Heartflow, Inc. (NASDAQ: HTFL) is delivering the kind of growth story investors usually hope to find before it becomes obvious: rapid revenue expansion, rising gross margins, stronger adoption of a second product line, and a materially higher full-year outlook. In a market…
The next compelling AI investment story may not sit in a data center. It may sit discreetly behind the ear.
Fortell, a privately held AI-hearing-aid company, is positioning itself at the intersection of custom silicon, machine learning, clinical care, and an enormous…
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) offer investors two distinctly attractive versions of the same biotech proposition: value creation through disciplined execution. Jazz is deploying capital to deepen an established rare-epilepsy franchise, while Eupraxia is assembling the…